The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the impact of prior induction cycle number on outcomes with gilteritinib in relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) based on data from the ADMIRAL and COMMODORE studies (NCT02421939 and NCT03182244, respectively). Dr Levis notes that the combined analysis of the two trials showed no significant impact of prior treatment on response to gilteritinib, indicating that patients with R/R FLT3-mutated AML respond better to gilteritinib than to salvage chemotherapy, regardless of prior treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Turns out there’s no impact there. This is the problem with subgroup analysis from the ADMIRAL trial. We did subgroup analysis and it suggested that maybe prior treatment numbers of cycles or the primary refractory state resulted in less of a response to gilteritinib compared to salvage chemotherapy. The COMMODORE trial did not find that in the least. And what we’ve done is combined the two trials to kind of definitively put the issue to rest...
Turns out there’s no impact there. This is the problem with subgroup analysis from the ADMIRAL trial. We did subgroup analysis and it suggested that maybe prior treatment numbers of cycles or the primary refractory state resulted in less of a response to gilteritinib compared to salvage chemotherapy. The COMMODORE trial did not find that in the least. And what we’ve done is combined the two trials to kind of definitively put the issue to rest. And no, there really isn’t, there’s no there there, it turns out. It doesn’t matter what you’ve got beforehand. If you’re relapsed/refractory, you’ll respond to gilteritinib better than salvage chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
